Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Derksen, R.H.W.M.
Right arrow Articles by Kappelle, L.J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Derksen, R.H.W.M.
Right arrow Articles by Kappelle, L.J.
Related Collections
Right arrow All Immunology
Right arrow All Cerebrovascular disease/Stroke
Right arrow Infarction
Right arrow All Clinical trials
Right arrow Clinical trials Observational study (Cohort, Case control)

Neurology 2003;61:111-114
© 2003 American Academy of Neurology
Brief Communications

Low dose aspirin after ischemic stroke associated with antiphospholipid syndrome

R.H.W.M. Derksen, MD PhD, P.G. de Groot, PhD and L.J. Kappelle, MD PhD

From the Department of Rheumatology and Clinical Immunology (Dr. Derksen), Thrombosis and Hemostasis Laboratory (Dr. de Groot), and Department of Neurology and Rudolf Magnus Institution of Neuroscience (Dr. Kappelle), University Medical Center, Utrecht, the Netherlands.

Address correspondence and reprint requests to Dr. Ronald H.W.M. Derksen, Department of Rheumatology and Clinical Immunology (F02.127), University Medical Center, PO Box 85500, 3508 GA Utrecht, The Netherlands; e-mail: r.h.w.m.derksen{at}digd.azu.nl

The authors describe course and outcome of eight patients with ischemic stroke as the first thrombotic manifestation of antiphospholipid syndrome who received low-dose aspirin as prophylactic treatment. During 8.9 years of follow-up, two patients had a recurrent stroke. Recurrent stroke rate per 100 patient-years on aspirin was 3.5 (95% CI 0.4 to 12.5).




This article has been cited by other articles:


Home page
 LupusHome page
T Tarr, G Lakos, H P Bhattoa, Y Shoenfeld, G Szegedi, and E Kiss
Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients
Lupus, January 1, 2007; 16(1): 39 - 45.
[Abstract] [PDF]

Home page
 Rheumatology (Oxford)Home page
G. Ruiz-Irastorza and M. A. Khamashta
Stroke and antiphospholipid syndrome: the treatment debate
Rheumatology, August 1, 2005; 44(8): 971 - 974.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
T. L. Ortel
Thrombosis and the Antiphospholipid Syndrome
Hematology, January 1, 2005; 2005(1): 462 - 468.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
S. R. Levine, R. L. Brey, B. C. Tilley, D. A. Triplett, J. L. P. Thompson, R. L. Sacco, J. P. Mohr, and for the APASS Investigators
Antiphospholipid Antibodies and Risk for Recurrent Vascular Events--Reply
JAMA, June 9, 2004; 291(22): 2702 - 2703.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by AAN Enterprises, Inc.